With treatment of the Arf1 inhibitors, we observed increased CCL5 levels in the serum of mice bearing CT26 tumor (Fig. 2c) and upregulated mRNA level of CCL5 in MYC-ON mouse liver cancer (Fig. 2d). Here, DDX53 is linked to liver cancer.